MRNA vs INCY — Key Metrics
| Metric | MRNA (MODERNA INC) | INCY (INCYTE CORP) |
|---|---|---|
| Price | 196.79 | 117.8 |
| Market Cap | 79.63 Billion | 24.01 Billion |
| P/E (TTM) | -27.8 | 56.36 |
| P/B (Quarterly) | 15.043 | 4.219 |
| P/S (TTM) | 31.53 | 3.99 |
| Net Profit Margin (TTM) | -110.5 | 6.7 |
| Gross Margin (TTM) | 28.0 | 92.7 |
| ROE (TTM) | -37.6 | 7.1 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Greatly Underperform
Greatly Outperform
Recommendation Summary
Stock MRNA is projected to greatly underperform the market, stock INCY is projected to greatly outperform the market. Upfront Recommendation: INCY.
Financial Metrics
| MRNA | Metrics | INCY |
|---|---|---|
| $196.79 | Price | $117.80 |
| — | Market Capitalization | — |
| 31.53 | Price to Sales | 3.99 |
| 112.62 | Price to Gross Profit | 4.31 |
| 29.96 | Price to R&D | 6.99 |
| 10.84 | Price to Current Assets | 4.35 |
MRNA vs INCY at a glance
Moderna INC (MRNA) and Incyte Corp (INCY) are both Biotechnology companies in the Healthcare sector. MRNA is the larger, at $79.6 billion in market value against $24.0 billion for INCY, about 3.3 times the size.
On trailing-twelve-month figures, MRNA trades at 31.5 times trailing sales and INCY at 4.0; net profit margins are -110.5% and 6.7%.
The Upfront Investment model currently rates MRNA Greatly Underperform and INCY Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.